• Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication
   
• Fevipiprant was well tolerated with adverse events balanced across treatment groups

Basel, Switzerland, December 16, 2019 – Novartis today announced topline results from its pivotal global Phase III LUSTER-1¹ and LUSTER-2² studies exploring the efficacy and safety of the investigational oral, once-daily, DP₂ receptor antagonist fevipiprant (QAW039). The …